Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, 325 Ninth Avenue, Box 359773, Seattle, WA 98104, USA.
Nat Rev Gastroenterol Hepatol. 2011 Jun;8(6):330-9. doi: 10.1038/nrgastro.2011.59. Epub 2011 Apr 19.
The incidence of Clostridium difficile infection (CDI) has increased since 2000, with greater numbers of severe cases reported, in part due to the emergence of a hypervirulent strain. Initial therapy with metronidazole is still recommended for mild to moderate CDI, but vancomycin is recommended for first-line therapy of severe CDI. Colectomy could be life-saving for some patients with severe disease that does not respond to maximal medical therapy. Recurrent CDI is a challenge to treat; no single effective therapy currently exists. Treatments include antibiotics, adjunct probiotics, fecal microbiota transplant and immune approaches. This Review discusses the various therapeutic approaches used for the treatment of refractory and recurrent CDI.
自 2000 年以来,艰难梭菌感染(CDI)的发病率有所增加,报告的严重病例数量也有所增加,部分原因是一种高毒力菌株的出现。对于轻度至中度 CDI,仍建议使用甲硝唑进行初始治疗,但对于严重 CDI,建议使用万古霉素作为一线治疗药物。对于一些对最大程度的药物治疗无反应的严重疾病患者,结肠切除术可能是救命的。复发性 CDI 是一个治疗难题;目前尚无单一有效的治疗方法。治疗包括抗生素、辅助益生菌、粪便微生物移植和免疫方法。本综述讨论了用于治疗难治性和复发性 CDI 的各种治疗方法。